Neurology Archives - Corcept Therapeutics

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, in Amyotrophic Lateral Sclerosis

October 9, 2025

Andrews, et al. • 2025 • NEALS 2025

DAZALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, In Amyotrophic Lateral Sclerosis

June 5, 2025

van den Berg et al. • 2025 • ENCALS 2025 Congress

Safety, Pharmacokinetics, and Pharmacodynamics of the Selective Glucocorticoid Receptor Modulator Dazucorilant in Healthy Volunteers

October 6, 2023

Donaldson et al. • 2023 • NEALS 22nd Annual Meeting

https://corcept.com/wp-content/uploads/2023/01/ENCALS2023-1.pdf

July 13, 2023

Donaldson et al. • 2023 • ENCALS Meeting 2023

DAZALS: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis

February 3, 2023

Mann et al • 2022 • European Network to Cure ALS (ENCALS)

Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).

November 15, 2017

Webster et al. • 2017 • Br J Pharmacol. 2017;174(5):396-408.

New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.

November 15, 2016

Pineau et al. • 2016 • Neurobiol Aging. 2016;45:109-122.

The selective glucocorticoid receptor modulator CORT108297 restores faulty hippocampal parameters in Wobbler and corticosterone-treated mice.

November 5, 2014

Meyer et al. • 2014 • J Steroid Biochem Mol Biol. 2014 Sep;143:40-8.

Age- and sex-dependent effects of early life stress on hippocampal neurogenesis.

May 15, 2014

Loi et al. • 2014 • Front Endocrinol (Lausanne). 2014;5:13.

Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

November 15, 2013

Baglietto-Vargas et al. • 2013 • Biol Psychiatry. 2013;74(5):357-66.